<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118989</url>
  </required_header>
  <id_info>
    <org_study_id>802193</org_study_id>
    <nct_id>NCT00118989</nct_id>
  </id_info>
  <brief_title>Curcumin for the Chemoprevention of Colorectal Cancer</brief_title>
  <official_title>Phase II Double Blind Placebo-Controlled Trial of Curcuminoids' Effect on Cellular Proliferation, Apoptosis and COX-2 Expression in the Colorectal Mucosa of Subjects With Recently Resected Sporadic Adenomatous Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Robert Wood Johnson Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aims:&#xD;
&#xD;
        -  To determine if curcuminoids modulate cellular proliferation as measured by&#xD;
           proliferating cell nuclear antigen (PCNA) in the colorectal mucosa of subjects with&#xD;
           previously resected adenomatous colonic polyps.&#xD;
&#xD;
      Hypothesis: Curcuminoids decrease cellular proliferation in the colorectal mucosa of subjects&#xD;
      with previously resected sporadic adenomatous colonic polyps.&#xD;
&#xD;
        -  To determine if curcuminoids modulate apoptosis, as measured by TUNEL assay, in the&#xD;
           colorectal mucosa of subjects with previously resected adenomatous colonic polyps.&#xD;
&#xD;
      Hypothesis: Curcuminoids increase apoptosis in colorectal mucosa of subjects with previously&#xD;
      resected sporadic adenomatous colonic polyps.&#xD;
&#xD;
        -  To determine if curcuminoids modulate COX-2 expression as measured by&#xD;
           immunohistochemical assays in subjects with previously resected adenomatous colonic&#xD;
           polyps&#xD;
&#xD;
      Hypothesis: Curcuminoids decrease colorectal mucosa COX-2 expression in subjects with&#xD;
      previously resected sporadic adenomatous colonic polyps.&#xD;
&#xD;
        -  To determine if curcuminoids modulate COX-2 activity as measured by urinary eicosanoids&#xD;
&#xD;
      Hypothesis: Curcuminoids decrease concentrations of urinary eicosanoids.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Could not be completed due to technology problems and cost constraints&#xD;
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cellular proliferation and apoptosis in the colonic mucosa</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>COX-2 expression and activity</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Adenomatous Polyps</condition>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcuminoids C3 Complex® to be taken orally via caps</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcuminoids</intervention_name>
    <description>Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months</description>
    <arm_group_label>Curcuminoids C3 Complex® to be taken orally via caps</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>Curcuminoids C3 Complex® (Sabinsa Co.)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18&#xD;
&#xD;
          -  A diagnosis for colon/rectal polyp resection, polypectomy&#xD;
&#xD;
          -  Subjects must be able to have the capacity and must be willing to provide informed&#xD;
             consent&#xD;
&#xD;
          -  Premenopausal women must be surgically incapable of childbearing or be using a&#xD;
             medically acceptable method of contraception (oral contraceptives, diaphragms, condoms&#xD;
             with spermicide, IUD, progesterone injection or implant) throughout the entire length&#xD;
             of the study&#xD;
&#xD;
          -  Men should wear condoms during the duration of the study given the unknown effects of&#xD;
             curcumin on sperm viability, fertility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or current history of colorectal cancer&#xD;
&#xD;
          -  Previous history of Familial Polyposis Syndromes&#xD;
&#xD;
          -  Previous history of inflammatory bowel disease&#xD;
&#xD;
          -  Previous surgery of the large bowel&#xD;
&#xD;
          -  Liver disease defined as AST and ALT&gt;3x upper limit of normal&#xD;
&#xD;
          -  Known history of gallstones, biliary colic or serum bilirubin &gt;2.0&#xD;
&#xD;
          -  Cardiac disease including myocardial infarction, congestive heart failure, arrhythmia&#xD;
&#xD;
          -  Renal disease defined as creatinine &gt;1.5&#xD;
&#xD;
          -  Hematopoietic disease defined as WBC&lt;4000, platelet count &lt;100,000, hemoglobin&lt;10.0 or&#xD;
             coagulation or bleeding disorder&#xD;
&#xD;
          -  Significantly impaired gastrointestinal function or absorption&#xD;
&#xD;
          -  Peptic ulcer disease&#xD;
&#xD;
          -  Active infection including viral, bacterial, atypical or fungal infections of any&#xD;
             organ system including HIV&#xD;
&#xD;
          -  Previous history of allergy to turmeric, Indian curries, aspirin or NSAIDs&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Dementia or other neurologic or psychiatric disease which may impede the ability to&#xD;
             follow the protocol&#xD;
&#xD;
          -  Inability to swallow pills&#xD;
&#xD;
          -  Prior or concurrent therapy with any herbal or dietary supplement containing&#xD;
             curcuminoids&#xD;
&#xD;
          -  Concurrent use of anticoagulants or antiplatelets including warfarin, clopidogrel&#xD;
&#xD;
          -  Prior or concurrent use of colorectal cancer chemopreventive agents including herbals:&#xD;
             Sulindac or other NSAIDs, aspirin, COX-2 inhibitors, 5-aminosalicylate, folate,&#xD;
             calcium, or their use within 14 days of enrollment&#xD;
&#xD;
          -  Concurrent use of immunosuppressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen E Guerra, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>July 2, 2005</study_first_submitted>
  <study_first_submitted_qc>July 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2005</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <keyword>chemoprevention</keyword>
  <keyword>adenomatous polyps</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomatous Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

